Ranibizumab Treatment in Age-Related Macular Degeneration: A Meta-Analysis of One-Year Results

被引:8
作者
Gerding, H. [1 ,2 ]
机构
[1] Klin Pallas, Dept Retinol, CH-4600 Olten, Switzerland
[2] Univ Munster, Dept Ophthalmol, Munster, Germany
关键词
age-related macular degeneration; AMD; wAMD; nAMD; anti-VEGF; ranibizumab; retina; macula; meta-analysis; review; VERTEPORFIN PLUS RANIBIZUMAB; INTRAVITREAL RANIBIZUMAB; CHOROIDAL NEOVASCULARIZATION; CLINICAL-PRACTICE; VISUAL-ACUITY; DOSING REGIMEN; EXUDATIVE AMD; SAFETY; BEVACIZUMAB; EFFICACY;
D O I
10.1055/s-0034-1368241
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: Although ranibizumab is widely used in age-related macular degeneration there is no systematic data available on the relation between treatment frequency and functional efficacy within the first 12 months of follow-up. Material and Methods: A meta-analysis was performed on available MEDLINE literature. 47 relevant clinical studies (54 case series) could be identified covering 11706 treated eyes. Non-linear and linear regressions were calculated for the relation between treatment frequency and functional outcome (average gain in visual acuity, % of eyes losing less than 15 letters of visual acuity, % of eyes gaining >= 15 letters) within the first year of care. Results: Mean improvement of average visual gain was + 4.9 +/- 3.6 (mean +/- 1 standard deviation) letters (case-weighted: 3.3 letters). The average number of ranibizumab injections until month 12 was 6.3 +/- 2.0 (case-weighted: 5.9). 92.4 +/- 3.9% of eyes (case-weighted: 91.9%) lost less than three lines of visual acuity and 24.5 +/- 8.2% (case-weighted: 23.3) gained more than 3 lines within the first year. Analysis of the relation between the number of injections and functional improvement indicated best fit for non-linear equations. A nearly stepwise improvement of functional gain occurred between 6.8 and 7.2 injections/year. A saturation effect of treatment occurred at higher injection frequency. Conclusions: The results of this meta-analysis clearly indicate a non-linear relation between the number of injections and functional gain of ranibizumab within the first 12 months of treatment. Treatment saturation seems to occur at a treatment frequency > 7.2 injections within the first 12 months.
引用
收藏
页码:427 / 431
页数:5
相关论文
共 50 条
[1]   Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review [J].
Bandukwala, Taha ;
Muni, Rajeev H. ;
Schwartz, Carol ;
Eng, Kenneth T. ;
Kertes, Peter J. .
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2010, 45 (06) :590-595
[2]   Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment [J].
Bloch, Sara B. ;
la Cour, Morten ;
Sander, Birgit ;
Hansen, Louise K. H. ;
Fuchs, Josefine ;
Lund-Andersen, Henrik ;
Larsen, Michael .
ACTA OPHTHALMOLOGICA, 2013, 91 (01) :42-47
[3]   A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration [J].
Boyer, David S. ;
Heier, Jeffrey S. ;
Brown, David M. ;
Francom, Steven F. ;
Ianchulev, Tsontcho ;
Rubio, Roman G. .
OPHTHALMOLOGY, 2009, 116 (09) :1731-1739
[4]   Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J].
Brown, David M. ;
Kaiser, Peter K. ;
Michels, Mark ;
Soubrane, Gisele ;
Heier, Jeffrey S. ;
Kim, Robert Y. ;
Sy, Judy P. ;
Schneider, Susan .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1432-1444
[5]   Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration [J].
Busbee, Brandon G. ;
Ho, Allen C. ;
Brown, David M. ;
Heier, Jeffrey S. ;
Suner, Ivan J. ;
Li, Zhengrong ;
Rubio, Roman G. ;
Lai, Phillip .
OPHTHALMOLOGY, 2013, 120 (05) :1046-1056
[6]   Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting [J].
Carneiro, Angela M. ;
Mendonca, Luis S. ;
Falcao, Manuel S. ;
Fonseca, Sofia L. ;
Brandao, Elisete M. ;
Falcao-Reis, Fernando M. .
CLINICAL OPHTHALMOLOGY, 2012, 6 :1149-1157
[7]   Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration [J].
Chakravarthy, Usha ;
Harding, Simon P. ;
Rogers, Chris A. ;
Downes, Susan M. ;
Lotery, Andrew J. ;
Wordsworth, Sarah ;
Reeves, Barnaby C. .
OPHTHALMOLOGY, 2012, 119 (07) :1399-1411
[8]   Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010 [J].
Cohen, Salomon Y. ;
Dubois, Lise ;
Ayrault, Sandrine ;
Dourmad, Pauline ;
Delahaye-Mazza, Corinne ;
Fajnkuchen, Franck ;
Nghiem-Buffet, Sylvia ;
Quentel, Gabriel ;
Tadayoni, Ramin .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2013, 251 (11) :2499-2503
[9]   Results of One-Year's Treatment with Ranibizumab for Exudative Age-related Macular Degeneration in a Clinical Setting [J].
Cohen, Salomon Y. ;
Dubois, Lise ;
Tadayoni, Ramin ;
Fainkuchen, Franck ;
Nghiem-Buffet, Sylvia ;
Delahaye-Mazza, Corinne ;
Guiberteau, Brigitte ;
Quentel, Gabriel .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (03) :409-413
[10]  
Cohen SP, 2013, SHOOTING FOR A CENTURY: THE INDIA-PAKISTAN CONUNDRUM, P33